Navigation Links
New Weight-Loss Drug Shows Promise in Early Study
Date:1/8/2008

But adverse effects include gastrointestinal problems, anxiety

TUESDAY, Jan. 8 (HealthDay News) -- An experimental weight-loss drug helped people shed pounds, but its adverse effects included gastrointestinal distress and psychiatric problems, scientists report.

Called taranabant, the drug was developed by Merck Research Laboratories, which funded the new research published in the January issue of Cell Metabolism.

"It suppresses food intake and increases your metabolism," explained Dr. Steven Heymsfield, global director of scientific affairs, obesity, for Merck Research.

The drug works by blocking the same pleasure centers in the brain that are triggered when marijuana smokers get hungry. Blocking these cannabinoid receptors reduces hunger and helps people lose weight, the researchers said.

Taranabant is in the same class of drugs as rimonabant (Acomplia), which the U.S. Food and Drug Administration has not yet approved due to concerns about the risk of suicidal thoughts among some users. Rimonabant is on the market in Europe, however.

In the new study on taranabant, "no suicidal thoughts were reported," Heymsfield said. But the question was not asked, he added, in a systemic way. For a larger, upcoming trial, it will be, he noted.

In this latest study, Heymsfield's team assigned 533 obese patients to receive either a placebo or one of four taranabant doses: 0.5, 2, 4 or 6 milligrams daily. A total of 358 patients finished the 12-week study.

While the placebo group lost about 2.6 pounds during the study, the 6-milligram taranabant group lost the most.

"Those who took the 6-milligram dose every day for 12 weeks lost about 11 pounds," Heymsfield said. They also followed a reduced-calorie eating plan but had no specific exercise plan.

In a separate study reported by the same group of scientists in the journal, the researchers gave 36 overweight or obe
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. NutriSystem Advances Weight-Loss Category
2. Studies Examine Life After Weight-Loss Surgery
3. Psychiatric Woes Can Postpone Weight-Loss Surgery
4. FTC Attacks Infomercial Marketer to Silence Best-Selling Authors Weight-Loss Tips
5. UMass Medical School study identifies the best weight-loss plans for heart health
6. Weight-Loss Surgeries Extend Lives
7. Shorter HCV treatment shows notable success
8. DNC: Rudy Shows Again Hes Out-of-Touch With Americas Priorities
9. Kaiser Permanente -- Group Health study shows depression worsens HIV treatment
10. Twins study shows genetic basis for face and place recognition
11. Fetal surgeon shows for first time that laser procedure may treat vasa previa
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Weight-Loss Drug Shows Promise in Early Study
(Date:5/29/2015)... 29, 2015 The report ... provides comprehensive information on the therapeutic development ... pipelines by identifying new targets and MOAs ... report on H1 2015 pipeline review of ... and 13 figures, spread across 47 pages ...
(Date:5/29/2015)... 29, 2015 The popular all-natural supplement ... rewards based L-Style Select Program that gives bonuses to ... limited to only 100 members per year, lucky members ... on one with fitness experts at Nuretix Research, and ... them provided that they attain and maintain their weight ...
(Date:5/29/2015)... For the third year, Nike Ultimate Camps will ... ultimate community an opportunity to experience ultimate training techniques in ... of the USAU Nike Ultimate Camp is to provide a ... character, and make lifelong friends. , The USAU Nike Ultimate ... skill and ability levels, ages 10-18. Camp will run from ...
(Date:5/29/2015)... Health DataPalooza is a national conference ... and foster the most effective and innovative ways to ... is hosted by the Health Data Consortium, which is ... promote and develop the use of open healthcare data. ... to narrow in on how to actually put the ...
(Date:5/29/2015)... NEW YORK (PRWEB) May 29, 2015 ... Medical Center has found that a urine test ... cancer with 92 percent accuracy. Dr. James McKiernan ... 2015 Annual Meeting Press Event. , Dr. ... John K. Lattimer Professor and chair of the ...
Breaking Medicine News(10 mins):Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 3Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 2Health News:Urine Test Detects Prostate Cancer with 92 Percent Accuracy, According to Study 3
... some experts, newly born neuronal stem cells in the adult ... these stem cells are to be utilized in this way, ... regulated. , A new study, led by Laurence Katz, ... of the North Carolina School of Medicine, suggests a way ...
... FALLS" , A study by Indiana University ... of their elderly study participants and their postural stability ... in line with recent findings by other researchers involving ... designed to probe cognitive function effective at identifying people ...
... of American,Physicians, Inc. (CAP) today announced that the exceptional ... has again,earned an A+ rating from A.M. Best Company, ... consecutive year that MPT has,achieved this rating., "We ... Rating again this year,",said CEO James L. Weidner. "It ...
... to millions of diabetics who are missed , , FRIDAY, ... for diabetes is being called for to help the ... disease, a new report says. , "Approximately 30 percent ... undiagnosed," study author Dr. Christopher Saudek, of Johns Hopkins ...
... & Asthma Network Mothers of Asthmatics Applauds FDA Public ... and Offers Critical Facts Patients Need to Know, ... their healthcare providers do not know that at the ... Today, FDA urged patients,still using chlorofluorocarbon (CFC) albuterol metered-dose ...
... EXTON, Pa., May 30 Isolagen(TM), Inc. (Amex:,ILE) ... notice from the staff,of the American Stock Exchange (AMEX) ... compliance did not demonstrate its ability,to regain compliance with ... (a)(i)-(iii) of the AMEX Company Guide within the,prescribed time ...
Cached Medicine News:Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Mutual Protection Trust Earns Third A+ Rating From A.M. Best 2Health News:Panel Calls for Better Diabetes Screening 2Health News:Get the Facts on the Albuterol Inhaler Transition 2Health News:Get the Facts on the Albuterol Inhaler Transition 3Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 3
(Date:5/28/2015)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... the Jefferies 2015 Healthcare Conference on Wednesday, June 3, ... New York .  Lexicon management will provide an ... A webcast of the presentation will be available ... version of the presentation will be available at ...
(Date:5/28/2015)... and DEKALB, Ill. , May ... Letter of Intent to explore an affiliation with ... months, KishHealth and NMHC will further define the ... approval. "KishHealth is recognized for their ... said Dean M. Harrison , President and ...
(Date:5/28/2015)... Today, the California State Senate approved legislation ... before prescribing the most addictive medications to help prevent ... SB 482, authored by Sen. Ricardo Lara ... prescribers to check the Controlled Substance Utilization Review and ... drugs, like OxyContin and other opioids, for the first ...
Breaking Medicine Technology:Lexicon To Present At The Jefferies 2015 Healthcare Conference 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 3California Senate Approves Legislation Requiring Physicians To Check State Database Before Prescribing Powerful, Addictive Medications, Says Consumer Watchdog 2
... one of the world,s leading research and advisory firms ... of branded erythropoietin stimulating agent (ESA) market share is ... the United States compared to biosimilar erosion seen in ... 2007. According to Biosimilars Advisory Service: ...
... YORK, Nov. 4, 2010 Reportlinker.com ... report is available in its catalogue: ... Cancer Overview - Metastatic gastrointestinal cancers ... to a lack of approved drugs ...
Cached Medicine Technology:Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe 2Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 2Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 3Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 4Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 5Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 6Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 7Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 8Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 9Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 10Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 11Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 12Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 13Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 14Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 15Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 16Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 17
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: